Skip to main navigation

Home
Overview
News & Events
- News Releases
- Presentations
Stock Information
- Stock Quote & Chart
Corporate Governance
SEC Filings
- SEC Filings
IR Resources

Presentations

Corporate Presentation

Investor Contact

Contact

Caroline Code
VP, Corporate Development & Investor Relations
ir@obsidiantx.com

Subscribe to our Email Alerts

Email Address Required

Home
About Us
Our Science
Our Lead Clinical Program
Investors & Media
Join Our Team
Contact

Privacy
Terms of Use

© 2026 Obsidian Therapeutics. All Rights Reserved.

Our programs, including OBX-115, and cytoDRIVE® Platform are investigational and have not been approved by the FDA or any other regulatory agency.

Search Investors

Search this site